Developmental Research Program

发展研究计划(DRP)摘要/摘要 本次孢子规划研究的发展研究计划(DRP)的目标是支持 开发并成功完成旨在实现以下目标的创新、高风险/高回报试点项目 了解或减少儿童急性淋巴细胞白血病(ALL)中基于种族的结局差异。 该项目将由内科科学家玛丽亚·莫妮卡·格拉马吉斯博士和菲利普·卢波博士共同领导。 分子流行病学家。Gramatges博士和Lupo博士在翻译研究方面都有很好的记录 研究儿童癌症治疗相关毒性的遗传和分子预测因素。他们的 相互补充的学科和合作历史证明了DRP坚定地致力于支持 多学科研究。DRP支持的项目可以是临床项目或转化性项目，但必须解决种族问题 所有与治疗有关的毒性(急性或迟发性)的差异。申请DRP飞行员补助金的资格将 延伸至参与此申请的机构的任何教职员工。建议书将使用以下工具进行评分 NIH的9分制，以及资金的选择将由DRP委员会共同决定。 DRP委员会的成员将在所有参与网站上平均分配，以确保公平和 奖项分配的透明度，并将包括在临床和翻译研究方面具有专业知识的教师 以及在参与赠款同行审查方面有良好记录的人。提供资金的标准将与 在上述集中地区被视为高风险/高影响的强大科学价值。 代表参与机构之间合作的提案也将被优先考虑 来自初级教员和新调查人员的提案(那些之前没有独立联邦资金的)和那些 被认为可能导致未来的独立供资。所有试点补助金将颁发为期一年，并提供 在第一年结束时有机会一次性续签一年。除了拨款审查和 在遴选过程中，DRP委员会将负责监测和监督资助项目，通过定期 审查进展情况和最终报告。DRP的核心任务是为获奖者提供资金 支持，2)使用核心设施，以及3)授奖期间的指导。总计75,000美元将是 预算用于资助第一年的三个试点奖，每个奖25 000美元，#年每年90 000美元 此后每年资助两次试点奖，外加两次续期，每次续期20,000美元。 所有试点授权PI将免费访问指定的核心，并将 需要使用至少一个核心。DRP委员会将为每个受资助的项目分配一个咨询委员会 具有相关专业知识的世卫组织将提供针对每个项目的指导和指导。的关键作用 咨询委员会将与DRP委员会一道，促进 Pilot授予独立资助的工作数据，并可能包含在未来的P50申请中。

DEVELOPMENTAL RESEARCH PROGRAM (DRP) SUMMARY/ABSTRACT The objective of the Developmental Research Program (DRP) of this SPORE planning study is to support the development and successful completion of innovative, high-risk/high-reward pilot projects that aim to understand or reduce outcome ethnicity-based disparities in childhood acute lymphoblastic leukemia (ALL). This program will be co-led by Dr. Maria Monica Gramatges, a physician scientist, and Dr. Philip Lupo, a molecular epidemiologist. Drs. Gramatges and Lupo each have strong track records in translational research investigating genetic and molecular predictors of treatment-related toxicities in childhood cancer. Their complementary disciplines and history of collaboration evidence a strong commitment of the DRP to supporting multidisciplinary research. DRP-supported projects may be clinical or translational, but must address ethnic disparities in ALL treatment-related toxicities (acute or late onset). Eligibility to apply for a DRP Pilot Grant will extend to any faculty member of an institution participating in this application. Proposals will be scored using the NIH 9 point system, and selection for funding will be jointly determined by the DRP Committee. Membership to the DRP Committee will be distributed equally across all participating sites to ensure equity and transparency in award distribution, and will include faculty with expertise in clinical and translational research and who have a strong track record of participation in grant peer review. Criteria for funding will be work with strong scientific merit that is perceived as high-risk/high-impact in the above listed areas of concentration. Proposals representing collaborations between participating institutions will also be prioritized, as will proposals from junior faculty and new investigators (those with no prior independent federal funding) and those considered likely to result in future independent funding. All Pilot Grants will be awarded for one year, with an opportunity for a one-time, one-year renewal at the end of the first year. In addition to grant review and selection, the DRP Committee will be responsible for monitoring and oversight of funded projects via regular review of progress and final reports. The DRP's core mission is to provide grant awardees with 1) funding support, 2) access to core facilities, and 3) mentorship during the award period. A total of $75,000 will be budgeted to support funding of three Pilot Awards in Year 1 at $25,000 per award, and $90,000 per year in each subsequent year to support funding two Pilot Awards per year plus two renewals at $20,000 per renewal. All Pilot Grant PI's will be provided with access to the designated Cores with no associated cost, and will be required to use at least one Core. The DRP Committee will assign each funded project an Advisory Committee with relevant expertise, who will provide mentorship and guidance that is specific to each project. A key role of the Advisory Committee, together with the DRP Committee, will be to facilitate the transition/development of Pilot Grant data to work that is independently funded, with potential inclusion in a future P50 application.